香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 二零二五年第三季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其附 屬公司統稱「本集團」）根據香港聯合交易所有限公司證券上市規則（「香港上市規 則」）第13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部 項下的內幕消息條文（定義見香港上市規則）而作出。 茲載列本公司在深圳證券交易所網站刊發的《凱萊英醫藥集團（天津）股份有限公 司二零二五年第三季度報告》，僅供參閱。本公司二零二五年第三季度報告（「二 零二五年第三季度報告」）以中、英文雙語編製。如兩個版本有任何不相符之處， 應以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 2025年第三季度報告 本公告乃根據證券及期貨條例（香港法例第571章）第XIVA部及香港聯合交易所有限公司 證券上市規則第13.09條而發表。 以下為上海醫藥集團股份有限公司2025年第三季度報告，其所載財務報告根據中國企業 會計準則編製，並且未經審計。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年十月三十一日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * 僅供識別 - 1 - 本公司董事會及全體董事保證本公告內容不存在任何虛假記載、誤導性陳述或者重大遺 漏，並對 ...

Haier Smart Home Co., Ltd.* 海爾智家股份有限公司 （於中華人民共和國註冊成立之股份有限公司） 股份代號：6690 2025年第三季度報告 本公告乃海爾智家股份有限公司（「本公司」）根據香港法例第571章《證券及期貨條例》 第XIVA部項下內幕消息條文及香港聯合交易所有限公司證券上市規則第13.09(2)條及 第13.10B作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 – 2 – 一、主要財務數據 （一） 主要會計數據和財務指標 單位：元 幣種：人民幣 本公司於2025年第三季度之財務數據乃根據中國企業會計準則編製並未經審計。合併 財務報表所載歸屬於母公司所有者的淨利潤及歸屬於母公司所有者權益與該等根據國 際財務報告準則編製的財務資料並無差異。 – 1 – 重要內容提示： 公司董事會及董事、高級管理人員保證季度報告內容的真實、準確、完整，不存在虛假記載、誤 導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 公司負責 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 中國人壽保險股份有限公司 CHINA LIFE INSURANCE COMPANY LIMITED 炷㕤ᷕ厗Ṣ㮹ℙ⚳姣Ⅎㆸ䩳ᷳ偉ấ㚱旸℔⎠炸! 本公告由中國人壽保險股份有限公司（「本公司」）根據證券及期貨條例（香港法例第571章） 第XIVA部的內幕消息條文以及香港聯合交易所有限公司證券上市規則第13.09(2)條及第 13.10B條而作出。 重要內容提示 炷偉ấẋ嘇;!3739炸! 2025年第三季度報告 單位：人民幣百萬元 | | | | | 本報告期末 比上年度末 | | --- | --- | --- | --- | --- | | 項目 | 本報告期末 | | 上年度末 | 增減變動幅度 | | 資產總計 | 7,417,981 | | 6,769,546 | 9.6% | | 歸屬於母公司股東的股東 | 625,828 | | 509,675 | 22.8% | | 權益合計 | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產 生或因依賴該等內容而引致的任何損失承擔任何責任。 截至二零二五年九月三十日止九个月期間 第三季度業績公告 上海復旦張江生物醫藥股份有限公司（「本公司」，聯同其附屬公司，「本集團」）之董 事會（「董事會」）欣然宣佈本集團截至二零二五年九月三十日止九個月期間按照中國企 業會計準則編製的未經審計財務資料。本公告乃根據香港法例第 571 章證券及期貨條例第 XIVA 部項下內幕消息條文及香港聯合交易所有限公司（「聯交所」）證券上市規則第 13.09(2) 和第 13.10B 條的要求作出。 主要財務數據 主要會計數據和財務指標 | | | | 單位：元 | 幣種：人民幣 | | --- | --- | --- | --- | --- | | | 截至二零二五年 | 比上年同期 | 截至二零二五年 | 比上年同期 | | 項目 | 九月三十日止 | 增減變動幅度 | 九月三十日止 | 增減變動幅度 | | | 三個月期間 | （%） | 九個月期間 | （%） | ...

Revenue and Profit - Revenue for the third quarter reached RMB 12,301,026,088.02, an increase of 24.88% compared to the same period last year[9] - Net profit attributable to shareholders was RMB 1,155,589,121.71, reflecting a growth of 35.80% year-over-year[9] - The net profit after deducting non-recurring gains and losses was RMB 718,347,769.07, a slight increase of 1.12% compared to the previous year[9] - Total revenue for the period reached RMB 37.16 billion, an increase of 8.2% compared to RMB 34.39 billion in the previous period[27] - Operating profit for the current period reached RMB 4,641,045,468.29, an increase of 20.6% from RMB 3,849,982,011.80 in the previous period[28] - Net profit attributable to shareholders of the parent company was RMB 3,920,367,724.61, up 25% from RMB 3,139,015,862.65 year-over-year[29] - Total comprehensive income for the current period amounted to RMB 4,115,715,418.49, compared to RMB 3,154,266,690.45 in the previous period, reflecting a growth of 30.5%[29] - Basic earnings per share increased to RMB 0.45 from RMB 0.38, representing a rise of 18.4%[29] Cash Flow - The cash flow from operating activities showed a significant increase of 137.31%, totaling RMB 2,866,113,330.72[9] - Cash flow from operating activities generated a net amount of RMB 2,866,113,330.72, significantly higher than RMB 1,207,754,698.86 in the previous period[31] - Cash inflow from investment activities totaled RMB 3,632,914,758.45, compared to RMB 2,653,293,585.32 in the previous period, marking a growth of 37%[33] - Cash outflow from investment activities was RMB 10,487,957,773.68, up from RMB 4,283,770,631.45, leading to a net cash flow from investment activities of -RMB 6,855,043,015.23[33] - Cash flow from financing activities showed a net increase of RMB 3,386,998,045.74, compared to a net decrease of RMB 505,061,294.18 in the previous period[33] - The total cash and cash equivalents at the end of the period were RMB 11,624,320,881.22, down from RMB 12,632,527,356.56 at the end of the previous period[34] - The impact of exchange rate changes on cash and cash equivalents was a positive RMB 70,832,665.22, compared to a negative impact of RMB 45,540,908.72 in the previous period[34] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 131,105,845,143.43, representing a growth of 5.95% from the previous year[12] - The company's total assets reached RMB 131.11 billion, an increase of 5.4% from RMB 123.75 billion at the start of the period[24] - Total liabilities increased to RMB 70.54 billion, compared to RMB 63.91 billion at the start of the period, marking an increase of 10.3%[23] - Long-term borrowings rose significantly to RMB 20.80 billion, up 34.5% from RMB 15.41 billion at the beginning of the period[23] - Short-term borrowings surged to RMB 3.00 billion, a significant increase from RMB 1.43 billion at the beginning of the period, representing a rise of 109.0%[21] - Non-current assets totaled RMB 48.33 billion, down from RMB 49.32 billion at the beginning of the period, a decrease of 2%[19] - Deferred income tax assets decreased to RMB 2.50 billion from RMB 2.64 billion, a decline of 5.3%[19] Revenue Breakdown - Domestic revenue decreased by 5.38% to RMB 15,842,269,469.66, while overseas revenue increased by 20.80% to RMB 21,313,388,603.33[12] - The weighted average return on equity was 6.74%, an increase of 1.24% compared to the previous year[9] - The company reported a 121.16% increase in trading financial assets due to increased purchases of financial products[15] - Investment income surged by 4872.09% primarily from the sale of shares in joint ventures[15] Expenses - Total operating costs amounted to RMB 33.47 billion, up 7.3% from RMB 31.19 billion in the prior period[27] - Research and development expenses increased to RMB 2.05 billion, reflecting a rise of 10.1% from RMB 1.86 billion year-over-year[27]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 中國太平洋保險（集團）股份有限公司 CHINA PACIFIC INSURANCE (GROUP) CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：02601） 2025 年第三季度報告 本公告由中國太平洋保險（集團）股份有限公司（「本公司」）根據《證券及期貨條例》 第 XIVA 部及香港聯合交易所有限公司證券上市規則第 13.09 條及第 13.10B 條而作出。 本公司 2025 年第三季度報告所載財務資料根據中國企業會計準則編制，且未經審計。 §1 重要提示 1.1 本公司董事會、監事會及董事、監事、高級管理人員保證季度報告內容的真實、準確、 完整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 1.2 本公司第十屆董事會第十八次會議於 2025 年 10 月 30 日審議通過了本公司《2025 年 第三季度報告》。應出席會議的董事 13 人，親自 ...

Financial Performance - For the third quarter of 2025, the company's operating revenue was CNY 4,707,210,451.20, a decrease of 40.25% compared to the same period last year[9] - The total profit for the quarter reached CNY 2,189,976,373.46, representing an increase of 51.45% year-over-year[9] - Net profit attributable to shareholders was CNY 1,647,276,650.82, up 38.35% from the previous year[9] - The basic earnings per share for the quarter was CNY 0.19, reflecting a 46.15% increase compared to the same period last year[9] - The net profit margin for the year-to-date period increased to 39.38% compared to the previous year[9] - Total operating revenue for the first three quarters of 2025 reached ¥12,708,369,810.92, a significant increase of 39.1% compared to ¥9,117,648,632.32 in the same period of 2024[34] - Net profit for the first three quarters of 2025 was ¥5,110,096,476.73, representing a 54.7% increase from ¥3,302,385,918.07 in the same period of 2024[36] - The company reported a total profit of ¥6,483,606,053.17, up 74.8% from ¥3,717,102,655.26 in the previous year[36] - The company reported a total profit of ¥5,057,308,499.09, an increase from ¥4,071,048,399.83 in the same period of 2024[52] Assets and Liabilities - As of September 30, 2025, total assets amounted to CNY 453,940,008,289.95, an increase of 8.67% from the end of the previous year[9] - Total assets as of September 30, 2025, amounted to ¥336.19 billion, up from ¥322.70 billion at the end of 2024, reflecting a growth of approximately 4.2%[46] - Total liabilities as of September 30, 2025, were RMB 372.01 billion, compared to RMB 336.34 billion at the end of 2024, marking an increase of around 10.59%[31] - The total liabilities as of September 30, 2025, were ¥260.96 billion, an increase from ¥246.85 billion at the end of 2024, indicating a rise of approximately 5.7%[48] - The company's total equity reached RMB 81.93 billion, slightly up from RMB 81.40 billion, indicating a growth of about 0.65%[32] - The company's total equity as of September 30, 2025, was ¥75.23 billion, slightly down from ¥75.85 billion at the end of 2024, showing a decrease of about 0.8%[48] Cash Flow - Cash flow from operating activities was 1,795,310,107.31, a significant improvement from -7,127,656,843.14 in the previous period[20] - Cash flow from operating activities generated a net cash inflow of ¥1,795,310,107.31, a significant recovery from a net outflow of ¥7,127,656,843.14 in 2024[40] - Cash flow from investment activities for the first three quarters of 2025 reached ¥28.17 billion, a significant increase from ¥15.27 billion in the same period of 2024, marking an increase of approximately 84.5%[42] - The net increase in cash and cash equivalents for the first three quarters of 2025 was ¥20.47 billion, contrasting with a decrease of ¥4.46 billion in the same period of 2024[44] - The ending balance of cash and cash equivalents as of September 30, 2025, was 62,749,422,278.24 RMB, up from 51,843,109,134.03 RMB in 2024, indicating an increase of about 21%[58] Shareholder Information - The number of common shareholders at the end of the reporting period was 183,844[21] - The largest shareholder, Sheneng (Group) Co., Ltd., holds 26.63% of the shares, totaling 2,262,428,700 shares[22] Investment and Income - Investment income increased by 43.01% to 5,831,352,862.52, driven by higher returns from financial instrument investments[20] - Net commission and fee income rose to ¥4,832,418,246.90, up 28.8% from ¥3,750,748,995.10 in the previous year[34] - Net commission and fee income surged to ¥2,864,881,854.87, up 67.0% from ¥1,715,781,507.47 year-over-year[50] Adjustments and Changes - The company has made adjustments to its revenue recognition policies in accordance with new accounting standards issued in July 2025[10] - The company adjusted its financial statements for 2024, with contract liabilities reduced by 112,332,096.75 RMB, resulting in an adjusted amount of 44,877,175.53 RMB[60] - Other business income for the first three quarters of 2024 was adjusted to 4,871,487,410.49 RMB, reflecting a decrease of 74,802,478.65 RMB[60] - Investment income for the first three quarters of 2024 was adjusted to 4,077,489,041.30 RMB, down by 90,247,698.34 RMB[60] Risk and Coverage Ratios - The risk coverage ratio improved to 397.11% from 373.48% year-over-year[12] - The liquidity coverage ratio was reported at 203.83%, slightly up from 202.82% at the end of the previous year[12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 新華文軒出版傳媒股份有限公司 XINHUA WINSHARE PUBLISHING AND MEDIA CO., LTD. （於中華人民共和國註冊成立之股份有限公司） （股份代號：811） 2025年第三季度報告 新華文軒出版傳媒股份有限公司（「本公司」或「公司」）董事（「董事」）會（「董事 會」）欣然呈遞本公司及其附屬公司（統稱「本集團」）截至2025年9月30日止前三季 度未經審計業績（「第三季度報告」）。本公告乃根據香港聯合交易所有限公司（「聯 交所」）證券上市規則第13.09(2)條及第13.10B條以及香港法例第571章證券及期貨 條例第XIVA部項下之內幕消息條文作出。 一、重要內容提示 公司董事會、監事會及董事、監事、高級管理人員保證第三季度報告內容的真 實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶 的法律責任。 公司負責人周青先生、主管會計工作負責人徐永平先生及 ...

Related Party Loans - The company has a related party loan of RMB 36,670,000 due on April 22, 2025[3] - An additional related party loan of RMB 2,323,000 is also due on April 22, 2025[3] - The total amount of related party loans is RMB 38,993,000[2] - The major shareholder intends to maintain and extend the related party loans despite their maturity[4] - The company will issue further announcements regarding the latest developments of the related party loans[4] Shareholder Transactions - The company’s major shareholder has agreed to sell 247,708,066 shares, representing approximately 54.69% of the total issued shares, to Hong Kong Shengyuan Holdings Limited[4]